{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:25Z","timestamp":1790662765073,"version":"4.1.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was recently approved for submental fat (SMF) reduction in the United States (Kybella) and Canada (Belkyra). The pivotal trials supporting these approvals revealed that ATX-101 is associated with common injection-site treatment reactions consistent with its mechanism of action and administration procedure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>The purpose of this study was to evaluate 4 patient experience management paradigms targeting the common injection-site adverse events of pain, swelling\/edema, and bruising after a single treatment session with ATX-101.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>In this double-blind, parallel-group, exploratory Phase 3b study (ClinicalTrials.gov identifier: NCT02007434), subjects with moderate to severe SMF were randomized 4:1 within each paradigm to receive ATX-101 2 mg\/cm<jats:sup>2<\/jats:sup> or placebo. In Paradigm 1, subjects received a cold pack application to the treatment area. In Paradigm 2, in addition to cold pack application, subjects were treated with topical lidocaine and injectable lidocaine containing epinephrine. In Paradigm 3, in addition to the interventions of Paradigm 2, subjects received loratadine and ibuprofen. Subjects in Paradigm 4 received the same interventions in Paradigm 3, plus application of a chin strap.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Eighty-three subjects were treated. In ATX-101\u2013treated subjects, peak pain occurred within 1 to 5 minutes of treatment, with median values at these time points ranging from 21.4 to 35.7 mm on a 100-mm pain visual analog scale (\u201cmild\u201d). Pain ratings reduced substantially by 15 minutes; at 4 hours after injection, pain was characterized as mild tenderness or mild achiness. Compared with cold alone, treatment with topical and injectable lidocaine reduced median peak pain by 17%. Addition of ibuprofen and loratadine resulted in a total reduction in pain by 40%. Peak swelling\/edema in ATX-101\u2013treated subjects was \u201cmodest,\u201d with mean values \u22641.7 (on a 0\u20135 scale) across all paradigms. Swelling\/edema was not substantially mitigated by the interventions, including ibuprofen, loratidine, and the use of a chin strap. Bruising associated with ATX-101 treatment was confined to the treatment area, with mean values between 1.0 and 1.4 on a 0-to-5 scale. Bruising was modestly reduced by injectable lidocaine with epinephrine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Results from this study support the safety of ATX-101 for SMF reduction, and demonstrate that pain and bruising associated with ATX-101 treatment can be mitigated by a series of simple measures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000000908","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T16:35:08Z","timestamp":1477586108000},"page":"S288-S299","source":"Crossref","is-referenced-by-count":33,"title":["Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat"],"prefix":"10.1097","volume":"42","author":[{"given":"Jeffrey S.","family":"Dover","sequence":"first","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Kenkel","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Lizzul","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Evidence Scientific Solutions, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick C.","family":"Beddingfield","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California;"},{"name":"Department of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Drs. Lizzul, Gross, and Beddingfield are former employees of Allergan plc. Current affiliation for Drs. Lizzul and Beddingfield is Sienna Biopharmaceuticals, Inc., Westlake Village, California. Current affiliation for Dr. Gross is Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/DSS.0000000000000578","article-title":"REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction","volume":"42","author":"Jones","year":"2016","journal-title":"Dermatol Surg"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2016.04.028","article-title":"ATX-101 for reduction of submental fat: a phase III randomized controlled trial","volume":"75","author":"Humphrey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","article-title":"Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain","volume":"4","author":"Jensen","year":"2003","journal-title":"J Pain"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill pain questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/jdv.12377","article-title":"Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study","volume":"28","author":"Ascher","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjd.12695","article-title":"Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study","volume":"170","author":"Rzany","year":"2014","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"R15-20230814","first-page":"AB15","article-title":"Clinically meaningful reduction in submental fat during and after treatment with ATX-101 in the US\/CAN phase 3 trials, REFINE-1 and REFINE-2 (abstract 294)","volume":"5","author":"Beer","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201611001-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:06:49Z","timestamp":1692040009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201611001-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000000908","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}